Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene Therapy

Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene Therapy

Clomiphene citrate (CC) has been reported as an effective add-on therapy to somatostatin analogs and dopamine agonists in patients with acromegaly accompanied by hypogonadism; its use as a single agent to treat acromegaly and associated hypogonadism following incomplete surgery has not been previous...

Full description

Bibliographic Details
Main Authors: Juan D. Palacios, Ricardo J. Komotar, Atil Y. Kargi
Format: Article
Language:English
Published: Hindawi Limited 2018-01-01
Series:Case Reports in Endocrinology
Online Access:http://dx.doi.org/10.1155/2018/7925019
id doaj-8bad60a3404e4639b87a7d0cde059294
record_format Article
spelling doaj-8bad60a3404e4639b87a7d0cde0592942020-11-24T22:00:11ZengHindawi LimitedCase Reports in Endocrinology2090-65012090-651X2018-01-01201810.1155/2018/79250197925019Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene TherapyJuan D. Palacios0Ricardo J. Komotar1Atil Y. Kargi2Diabetes & Endocrinology Institute at Renaissance, Edinburg, TX 78539, USADivision of Neurosurgery, University of Miami Miller School of Medicine, Miami, FL 33136, USADivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USAClomiphene citrate (CC) has been reported as an effective add-on therapy to somatostatin analogs and dopamine agonists in patients with acromegaly accompanied by hypogonadism; its use as a single agent to treat acromegaly and associated hypogonadism following incomplete surgery has not been previously reported. We report the first case in which clomiphene was utilized as a single agent for the dual management of acromegaly and hypogonadism, not controlled by pituitary surgery alone. The treatment was well tolerated and proved to be effective after a process of treatment withdrawal and reintroduction. We propose that clomiphene may be considered as a cost-effective oral treatment option in select cases of hypogonadal acromegaly.http://dx.doi.org/10.1155/2018/7925019
collection DOAJ
language English
format Article
sources DOAJ
author Juan D. Palacios
Ricardo J. Komotar
Atil Y. Kargi
spellingShingle Juan D. Palacios
Ricardo J. Komotar
Atil Y. Kargi
Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene Therapy
Case Reports in Endocrinology
author_facet Juan D. Palacios
Ricardo J. Komotar
Atil Y. Kargi
author_sort Juan D. Palacios
title Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene Therapy
title_short Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene Therapy
title_full Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene Therapy
title_fullStr Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene Therapy
title_full_unstemmed Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene Therapy
title_sort successful treatment of acromegaly and associated hypogonadism with first-line clomiphene therapy
publisher Hindawi Limited
series Case Reports in Endocrinology
issn 2090-6501
2090-651X
publishDate 2018-01-01
description Clomiphene citrate (CC) has been reported as an effective add-on therapy to somatostatin analogs and dopamine agonists in patients with acromegaly accompanied by hypogonadism; its use as a single agent to treat acromegaly and associated hypogonadism following incomplete surgery has not been previously reported. We report the first case in which clomiphene was utilized as a single agent for the dual management of acromegaly and hypogonadism, not controlled by pituitary surgery alone. The treatment was well tolerated and proved to be effective after a process of treatment withdrawal and reintroduction. We propose that clomiphene may be considered as a cost-effective oral treatment option in select cases of hypogonadal acromegaly.
url http://dx.doi.org/10.1155/2018/7925019
work_keys_str_mv AT juandpalacios successfultreatmentofacromegalyandassociatedhypogonadismwithfirstlineclomiphenetherapy
AT ricardojkomotar successfultreatmentofacromegalyandassociatedhypogonadismwithfirstlineclomiphenetherapy
AT atilykargi successfultreatmentofacromegalyandassociatedhypogonadismwithfirstlineclomiphenetherapy
_version_ 1725844795056717824

Similar Items